# Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
> Note: PeptIQ is not a medical provider. Petrelintide is investigational. Exact milligram labels for all Phase 2 arms may remain partially masked in topline releases — do not invent DIY doses from forum posts. Educational content only.
Petrelintide is a long-acting human amylin analog from Roche/Genentech and Zealand Pharma. It sits in the same strategic lane as cagrilintide and eloralintide: weekly satiety biology that is related to, but distinct from, GLP-1.
Quick Answer: How Is Petrelintide Dosed?
From public ZUPREME-1 communications:
| Design element | What was tested |
|---|---|
| Route | Subcutaneous |
| Cadence | Once weekly |
| Arms | Five active dose levels + placebo |
| Escalation | Dose increased about every 4 weeks |
| Primary efficacy window highlighted | Weight change at week 28 (all arms beat placebo) |
| Longer readout | Through week 42, with additional follow-up planned for congress presentation |
Topline coverage has emphasized efficacy and tolerability more than publishing a full public milligram table for every arm. Until the full congress dataset posts dose-by-dose mg, treat "five weekly arms + q4w escalation" as the accurate dosing vocabulary.
ZUPREME-1 Results Snapshot
ZUPREME-1 enrolled 493 adults with overweight or obesity (mean BMI ~37), in a relatively gender-balanced cohort, on lifestyle counseling plus weekly petrelintide or placebo.
Public ADA / Healio-style summaries reported:
- Clinically meaningful weight loss in every active arm vs placebo at the primary 28-week analysis
- At 42 weeks, weight loss up to about 10.7% at the highest petrelintide dose vs about 1.7% placebo
- Investigators highlighted a very well tolerated profile relative to typical GLP-1 expectations in early commentary
That combination — solid double-digit loss with a tolerability narrative — is why petrelintide searches are climbing beside eloralintide and CagriSema.
Why Escalation Every 4 Weeks Matters
Amylin agonists share a GI / early-fullness risk with incretins. A four-week step schedule is the same titration philosophy that works for orforglipron and many GLP-1 labels:
- Start low enough to adapt
- Hold each step long enough to read nausea and meal-size collapse
- Only then climb
- Protect protein and training the whole way
If you are building a tracking template for any future labeled amylin analog, copy that cadence into your log even before milligrams are public.
